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Abstract
Background/Aim.  Balloon dilatation is a standard ap-
proach to the initial achalasia treatment. Modified dilatation
is also applied to rise efficacy and to lower complications.
Methods. A total of 57 patients were analysed within a me-
dian follow-up of 8.2 years. No premedication was used,
dilatation was performed up to the pain treshold, while in-
troduction and positioning of a dilatator was done in com-
bination of endoscopic and radiological control. Dilatation
effect was estimated by both Kim Symptom Scoring and
objective parameters: body weight rise and radiological
scintigraphic findings. Results. Excellent and good results
were obtained  in 50 (88%) of the patients, while in 7 (12%)
of the patients surgery was performed. There was no differ-
ence in dilatation efficacy regarding sex of the patients, but
the results were better in the patients above 40 years. Dura-
tion of symptoms, body weight loss, esophageal lumen
width do not indicate the definitive dilatation outcome.
Esophageal scintigraphy and body weight increase were in a
direct correlation with the effect of dilatation measured with
the Kim Symptom Scoring. After the one to two repeated
dilatations the efficacy increased from 74% to 88% justify-
ing the repetition of dilatation. In 2 (3.57%) of the patients,
that is in 2.65% of the totally dilated patients, perforation
was recorded. There was no lethal outcome of dilatation,
and the other complications were not clinically significant.
Conclusion. Modified balloon dilatation can be recom-
mended for initial method in achalasia treatment due to
high efficacy, easy performance in daily hospital while com-
plications are in standard range.
Key words:
esophageal achalasia; radionuclide imaging; balloon
dilatation; prognosis.
Apstrakt
Uvod/Cilj. Balon dilatacija je standardni pristup u poÿetnom
leÿenju ahalazije. Primenjena je  „modifikovana“ tehnika di-
latacije u leÿenju ahalazije u cilju poveýanja efikasnosti i sma-
njenja komplikacija. Metode. Analizirano je 57 bolesnika sa
medijanom praýenja od 8,2 godine. Nije korišýena premedi-
kacija, dilatacija je vršena do praga bola, a uvoĀenje i pozicio-
niranje dilatatora vršeno je kombinacijom endoskopske i ra-
diološke kontrole. Efekat dilatacije odreĀen je kombinacijom
Kimovog sistema za ocenjivanje simptoma i objektivnih pa-
ramatara: porasta telesne mase i radioloških scintigrafskih na-
laza. Rezultati. Odliÿni i dobri rezultati postignuti su kod 50
(88%) bolesnika, a kod 7 (12) nisu postignuti željeni rezultati i
kod njih je primenjena klasiÿna hirurška intervencija. Nije bilo
razlika u efkasnosti dilatacije u odnosu na pol bolesnika, ali
bolesnici stariji od 40 godina imali su bolje rezultate. Trajanje
simptoma, gubitak telesne mase i širina lumena jednjaka pre
dilatacije nisu ukazivali na definitivni ishod dilatacije. Scinti-
grafija jednjaka i porast telesne mase bilii su u direktnoj kore-
laciji sa efektom dilatacije odreĀenim Kimovim sistemom za
ocenjivanje simptoma. Posle ponovljene jedne do dve dilata-
cije, efikasnost je porasla sa 74% na 88%, što ukazuje na op-
ravdanost ponavljanja dilatacije. Kod 2 (3,57%) bolesnika,
odnosno kod 2,65% svih dilatiranih, zabeležena je perforacija
jednjaka. Smrtnih ishoda dilatacije nije bilo, a ostale kompli-
kacije nisu bile od kliniÿkog znaÿaja. Zakljuÿak. Modifikova-
na balon dilatacija može se preporuÿiti kao poÿetna metoda u
leÿenju ahalazije zbog visoke efikasnosti, jednostavog izvoĀe-
nja u dnevnoj bolnici, uz komplikacije koje se kreýu u sta-
ndardnim okvirima.
Kljuÿne reÿi:
jednjak, ahalazija; scintigrafija; dilatacija balonom;
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Introduction
Achalasia is a serious neuromuscular disorder of the
esophagus with no peristaltic activity of its body and espe-
cially the failure of the lower esophageal sphincter (LES) to
relax with swallowing 
1. This functional disorder leads to
food and liquid retention in the esophagus thus causing dys-
phagia, regurgitation, pain in the chest, loss in body weight
and, sometimes, bronchopulmonary infections due to aspira-
tion of esophageal contents. Etiology of achalasia has not
completely been understood 
2. The occurrence of antibodies
in the region towards the myenteric plexus is very likely to
suggest a basically autoimmune disorder, but it remains un-
known whether it is the primary or secondary defect 
3, 4.
Maintaininig of the LES tonic pressure is a complex and
poorly explained phenomenon 
5, while a recent hypothesis
says that the LES tonus results from the balance of excitatory
(cholinergic and substances P) and inhibitory (vasoactive
intestinal peptide and nitric monoxide) effects 
3, 6. Thus,
achalasia could be taken as nitrinergic neuritis that leads to
late LES relaxation with swallowing 
4.
It is not possible to restore motility of esophagus with
achalasia, so the options in achalasia treatment are of pallia-
tive type either conservative or surgical 
5. It seems that the
only way to improve esophageal emptying is to reduce the
resistance to the level of LES 
7, 8. Several methods are avail-
able for the treatment of achalasia, namely medicamentous
(nitrites, calcium antagonists, botulinum toxin), dilatation
and surgical treatment including laparascopic cardiomyot-
omy 
9–11.
Most often performed conservative method for the
treatment of achalasia is dilatation. Wether to initially use
surgery or dilatation in achalasia treatment is a not yet re-
solved dilemma 
12–16.
It is known that many factors affect the efficacy of ba-
loon dilatation in achalasia treatment. The aim of this study
was to examine the possibility to rise efficacy and reduce
complications in a patients with achalasia by the use of a
modified baloon dilatation.
Methods
A total of 57 patients were treated by the use of balloon
dilatation in a 16-year period. The average follow-up period
was 8 years and 2 months. The diagnosis of achalasia was
confirmed in all the patients on the basis of clinical exami-
nation, endoscopy, radiography, manometric and scin-
tigraphic findings. Children, psychotic and uncooperative
patients were excluded from the study. Dilatation was per-
formed also in the patients with the law Karnofsky status,
while those with serious cardiovascular diseases, such is un-
stable angina pectoris, were excluded from the study. The
patients with tortuous, “sigmoid” esophagus, as well as those
with hiatal hernia were also treated.
The basic standardized principles of the dilatation tech-
nique suggested by the National Medical Center, Betheseda,
USA were applied including no premedication with diaze-
pam, midazolam, pethidine, atropine, nor any other medica-
tions; endoscopic and radiographic positioning of a balloon
(baloon widening with hydrosoluble contrast agent), and
balloon widening up to above the pain threshold were sig-
nalled by a patient.
Dilatation was performed by the use of a Regiflex dila-
tator (Boston, USA), made of a special plastic material filled
with a gas or liquid, affecting radially a reduced part of the
esophagus.
Dilatation efficacy degree was estimated with the
symptom score suggested by Kim et al. 
9. The symptom
score for dysphagia, regurgitation, chest pain and heartburn
(pyrosis) was calculated by multiplying the frequency of
symptoms and their intensity. On the basis of the total
symptom score the patients were divided into three groups
regarding the response to balloon dilatation: the group I with
excellent an good results (implying the total symptom score
reduction by 50% or more as compared with the initial
value), the group II with the result improvement (the total
symptom score reduced by 50% to 25%), and the group III
with the bad result (the total symptom score not reduced by
25% or less).
Results
Out of 57 analysed patients, there were 32 (57%) males
and 25 (43%) females, the ratio being 1.2 : 1 (Figure 1).
3
9
8
5
3
22
1
55
6
4
3
1
0
1
2
3
4
5
6
7
8
9
10
<20 20-29 33-39 40-49 50-59 60-69 >70 Years
No of  patients
male
female
Fig. 1 – Age of the patients with achalasia.
The disease was most common in the males from the
age group 20–30 years, and the females from the age group
40–49 years, the average age being 43 years. Up to 40, there
were 31 patients, while above 40 there were 26 patients. The
youngest patient was 16, and the oldest 83. Ther was no sig-
nificant correlation found between the efficacy of balloon
dilatation and sex distribution of the patients.
There was a correlation found between the efficacy of
balloon dilatation and the age of the patients. The patients
above 40 had better prognosis regarding dilatation success as
compared to those below 40 years of age (Table 1).
The effect of dilatation evaluated by the use of symp-
tom score suggested excellent (42) and good results (8) in 50
(89%) of the patients regarded as a complete recovery from
the disease, while in 7 (11%) of the patients the results were
bad including two patients with a perforation.
The majority of patients had symptoms for 1–5 years.
In three patients symptoms were present for more than 12Volumen 70, Broj 10 VOJNOSANITETSKI PREGLED Strana 917
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years, although radiographically it was decompensated
achalasia. In the younger patients there was a shorter period
of symptoms prior to dilatation. Out of the 10 patients with
symptoms more than 10 years, 9 were above 40.
There was no significant correlation found between the
efficacy of balloon dilatation and the period of symptoms
present prior to dilatation. The duration of symptoms was
found not to have a prognostic significance for a final out-
come of dilatation. A few excellent and good results were
achieved in the patients with a longer disease presence, and a
few bad results in the patients with a short period of symp-
toms presence (Table 2).
Loss in body weight is the most common sign of the
disease. The highest number of the patients lost 10 kg of
body weight (Table 3).
There was no significant correlation found between the
efficacy of balloon dilatation and the loss of body weight.
The success od dilatation could not be predicted on the basis
of body weight loss.
A total of 54 patients showed loss in body weight. Six
months after the dilatation the majority of the patients (n =
30) gained 1–10 kg of body weight. The three patients
gained even more than 20 kg of body weight, while in 11 of
the patients there was no increase in body weight (Table 4).
There was a significant correlation between the efficacy
of balloon dilatation and the increase of body weight in the
patients after the dilatation. Body weight increase is regarded
to be an objective parameter for monitoring the efficacy of
dilatation and suggests a final outcome of the therapy.
The majority of patients had esophagus lumen width of
3.5 cm to 6 cm in esophagogram, while in 13 of the patients
it was more than 6 cm, implying that they were in decom-
pensation stage (Table 5).
There was no significant correlation found between
esophageal dilatation degree before the dilatation and the ef-
ficacy of balloon dilatation.
Table 1
Long-standing results of dilatation in the patients with achalasia under 40 and above 40 years of age
Dilatation efficacy Age of patients (years) excellent good poor total
< 40 21 (36.84) 5 (8.77) 5 (8.77) 31 (54.38)
> 40 21 (36.84) 3 (5.26) 2 (3.50) 26 (45.61)
Total 42 (73.68) 8 (14.03) 7 (12.28) 57 (100)
Data are present as number (%) of patients.
Table 2
Association of symptoms duration and dilatation efficacy
Dilatation efficacy Duration of symptoms (years) excellent good poor total
< 1 6 (15.53) 2 (3.51) 1 (1.75) 9 (15.79)
1–5 19 (33.33) 3 (5.26) 2 (3.51) 24 (42.11)
5–10 8 (14.03) 2 (3.51) 2 (3.51) 12 (21.05)
> 10 9 (15.79) 1 (1.75) 2 (3.51) 12 (21.05)
Total 42 (73.68) 8 (14.03) 7 (12.28) 57 (100)
Data are present as number (%)  patients.
Table 3
Association of body weight loss and dilatation efficacy
Dilatation efficacy Weight loss (kg) excellent good poor total
No loss 3 (5.26) 1 (1.75) 1 (1.75) 5 (8.77)
< 5 12 (21.05) 2 (3.51) 2 (3.51) 16 (28.07)
5–10 14 (24.56) 3 (5.26) 2 (3.51) 19 (33.33)
> 10 13 (22.81) 2 (3.51) 2 (3.51) 17 (29.82)
Total 42 (73.68) 8 (14.03) 7 (12.28) 57 (100)
Data are present as number (%) of patients.
Table 4
Association of body weight increase after dilatation and dilatation efficacy
Dilatation efficacy Results of dilatation excellent good poor total
Body weight increase (kg)
no change 3 (5.26) 3 (5.26) 5 (88.78) 5 (8.78)
< 5 14 (24.56) 2 (3.51) 1 (1.75) 16 (28.07)
6–10 11 (24.56) 1 (1.75) 1 (1.75) 19 (33.33)
> 10 14 (19.30) 2 (3.51) 0 (0) 17 (29.82)
Total 42 (73.68) 8 (14.03) 7 (12.28) 57 (100)
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Esophagus scintigraphy is a non-invasive, simple and
reliable method which in physiological manner provides a di-
rect quantification of esophageal motor function, that is eso-
phageal clearance (Table 6, Figures 2 and 3).
A
Fig. 2 – Typical radiological image of achalasia before (left)
and after (right) successful dilatation.
Fig. 3 – Radionuclide imaging in achalasia before (left) and
after (right) dilatation.
There was a significant correlation found between bal-
loon dilatation efficacy and esophageal emptying measured
by the use of scintigraphy.
In 40 (70%) of the patients one dilatation was per-
formed, in 14 (25%) two, while in three (5%) of the patients
three dilatations were done, thus a total of 74 dilatations
were performed in 57 patients. Dilatation was repeated not
earlier than three months after the previous one. The majority
of patients were motivated for dilatation repetition, while the
one was referred to esophagomyotomy due to failure in the
first dilatation (Table 7).
Excellent and good results were obtained in two thirds of
the patients after first dilatation, indicating best results of first
dilatation. Second and third dilatations were justified by the
fact that another 9 (15%) of the patients showed excellent re-
sults after repeated dilatation. Final excellent and good results
were shown by 50 out of the total of 57 patients, and dilatation
success rate was increased from 67% to 89%.
Esophageal perforation is the most common complication
of balloon dilatation causing morbidity that could lead to death.
In 2 (3.57%) dilated patients there was a perforation, that is
in 2.60% out of all dilatations. The diagnosis in both patients
was made immediatelly after dilatation, then they were success-
fully operated on. There were no lethal outcomes. In 2 (3.57%)
of the patients submucosal damage was registered. They were
conservatively treated. In 23 (40%) of the patients there was
blood on a balloon dilatator indicating mucosal damage and
dilatation efficacy. It should not be considered as complication.
Early complications (prolonged pain, feaver, gastroin-
testinal bleeding) were present in 7 of the patients, but only
temporary. A total of 3 patients had prolonged chest pain for
8–20 h. Esophagogram was repeated with no perforations
found. Anxiolytics, not analgetics, were used for treatment.
In 3 patients there was temperature increase above 38°C, and
in one melena with hematocrit reduction to 0.08%.
Late complications were registered in 8 of the patients.
They were mostly manifested by stage 1 esophagitis, and in
2 of the patients by stage 2, and in 1 by stage 3 esophagitis.
Table 5
Association of esophageal dilatation and dilatation efficacy
Dilatation efficacy Esophageal dilatation width (cm) excellent good poor total
< 3.5 13 (22.81) 3 (5.26) 2 (3.51) 18 (31.59)
3.5–6 20 (35.09) 4 (7.02) 2 (3.51) 26 (45.60)
> 6 9 (15.79) 1 (1.75) 3 (5.26) 13 (22.81)
Total 42 (73.68) 8 (14.03) 7 (12.28) 57 (100)
Data are present as number (%) of patients.
Table 6
Association of radionuclide discharge and dilatation efficacy
Dilatation efficacy Radionuclide discharge (%) excellent good poor total
> 50 23 (56.09) 0 (0) 0 (0) 23 (56.09)
< 50 8 (19.51) 1 (2.44) 4 (9.76) 13 (31.71)
No change 0 (0) 4 (9.76) 1 (2.44) 5 (12.20)
Total 31 (75.60) 5 (12.20) 5 (12.20) 41 (100)
Data are present as number (%) of patients.Volumen 70, Broj 10 VOJNOSANITETSKI PREGLED Strana 919
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There was no carcinoma found in any patients treated
by dilatation, indicating good evaluation of the disease prior
to dilatation.
Discussion
Sir Thomas Willis was the first one to report on achala-
sia in 1672, and then to perform dilatation on the same pa-
tient by the help of a whale bone 
1. Three and a half centuries
later there are no significant changes except for technical
improvements of the method 
16–20. Today achalasia treatment
methods are still palliative, while esophageal emptying com-
pletely depends upon gravitation 
21–23.
Medicaments such as nitroglycerin, isosorbide dinitrate,
calcium antagonists are advised to patients with mild symp-
toms 
24, 25. Botulinum toxin in achalasia treatment was reported
first in Lancet in 1993
 26. Application of botulinum toxin in
achalasia is safe, simple and efficient, and till now indicative
in patients with a high risk for dilatation or cardiomyotomy 
27.
Today there are two options of basic approach to the
treatment of achalasia: dilatation and surgery including numer-
ous modifications of both methods. Research for alternative
endoscopic modalities for achalasia treatment is under way all
the time. Reducing pressure of diffuse esophageal spasm (DES)
by ethanolamine, used in scleroterapy of esophageal varices,
has not found wider application, and the results have been fol-
lowed up in short-term at the level of dilatation 
28.
In 1991 laparoscopic myotomy as possible option in
achalasia treatment was introduced while the results were
shown later 
29, 30. Excellent results in 88% of patients indicate
that laparoscopic myotomy is a method of choice in achala-
sia management 
31. In his study, Richter 
32 tried to solve the
dilemma whether to use laparoscopic myotomy or dilatation
in achalasia management.
Initial achalasia treatment method is a personal choice of
the physician, attitude of a medical institution and capability of
teams for surgery or dilatation 
1. Here, we exclusively used
dilatation as an initial method in achalasia treatment.
The second question to answer is what dilatation tech-
nique to use for achalasia treatment. Balloon dilatation is a tra-
ditional method for non-surgical achalasia treatment with the
aim to mechanically cut muscle fiber of DES. Vantreppen and
Hellemans 
5 gave the greatest contribution to the promotion of
this method. Many dilator types were used in the past: Brown-
McHardy, Hurst, Tucker, Mosher, Rider-Moller etc. In 1981
the results obtained by dilators positioned under endoscopic
monitoring were published 
1. Dilators with polyurethane ba-
loon (Rigiflex) came into use 15 years ago. One of Rigiflex
balloon most significant advantages is its possibility to be in-
flated only up to a clearly set radius. Richter 
32 comes to a con-
clusion that the use of one or the other dilator depends more
upon the endoscopist’s experience than on the instrument type
itself. Pneumatic dilatation is considered by the majority of
authors to be the most efficient nonsurgical treatment of acha-
lasia 
33–36. Dilatation technique has not yet been standardized
in spite of its wide application in achalasia treatment 
37–39.
Values of insufflation pressure that cause muscle fibres
splitting have not been determined so far. Insufflation pres-
sure ranging from 200 mmHg to 300 mmHg (5 psi – pound
square inch) is used in Europe and Japan, while 450–740
mmHg (9–15 psi) is used in the USA. The higher the pres-
sure, the efficient the method, but also the most frequent per-
foration. It is advisible to determine the pressure under which
the efficacy increases with acceptable range of complica-
tions. By analysing 270 perforations, Borotto et al. 
40 con-
clude that the upper limit of 11 psi allows a balloon insuffla-
tion with no higher risk for perforation.
The dilemma about dilatation balloon width has not been
resolved, as well. Vantreppen and Helllemans 
5 suggest a bal-
loon of 4 cm width, while others suggest to start dilatation
with a 3 cm balloon and to performe repeated dilations by the
use of wider diameters, but not wider than 4.5 cm 
20, 41.
The mentioned dilemmas about defining insufflation
pressure and balloon diameter we solved by insufflating
balloon up to just above pain treshold since that is the pres-
sure under which DES muscle fibers split. It is individual to
each patient. In order not to change pain threshold, however,
we do not perform premedication, which makes the said
method less comfortable to patients.
Insufflation duration for one treatment takes 15–60 s in
the USA, and 1–3 min in Europe and Japan. In a prospective
study Kim et al.
9 came to a conclusion that insufflation tak-
ing more than 1 min do not affect the results of dilatation and
that muscle fibers probably split within the first 5–10 s. Du-
ration of maximal insufflation pressure do not affect signifi-
cantly the results of dilatation, thus leaving to the therapist to
make a choice 
21. Like the majority of authors, we decided
for maximal insufflation pressure in one minute 
42.
Balloon insufflation for one treatment has to be re-
peated at least once by rising insufflation pressure in the sec-
ond dilatation or by widening the diameter of a balloon 
5.
There are the authors who consider that dilatation has not to
be repeated within one treatment 
9, 43. We repeat dilatations
within a treatment up to above pain treshold since we sup-
pose that a way to rise dilatation efficacy.
Richter 
23 and Cohen et al. 
44 consider fluoroscopy neces-
sary, while the majority of authors consider it unnecessary in
the control of dilatation and to be used only from time to time.
Table 7
Association of the number of dilatations and dilatation efficacy
Dilatation efficacy Number dilatation excellent good poor total
One 33 (57.89) 7 (12.28) 17 (29.82) 57 (76.00)
Two 8 (14.03) 2 (3.50) 6 (10.52) 16 (28.07)
Three 1 (1.75) 1 (1.75) 1 (1.75) 3 (3.95)
Total    42 (73.67) 10 (8.77) 24 (41.09) 76 (100)
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With the Witzel dilator which is introduced and positioned un-
der endoscopic vision there is no need for fluoroscopy. Com-
bining endoscopic/fluoroscopic vision makes it possible to
take advantages of both methods and to minimize their disad-
vantages. We introduce a dilator under endoscopic vision
which is very safe even in sigmoid esophagus, thus reducing
exposition to radiography. Fluoroscopy allows good balloon
positioning and its keeping in the correct position. The use of a
contrast agent in balloon dilatation make it possible to mesure
balloon width ant to register all that at radiography.
Esophagogram is required only in patients with simp-
toms indicating perforation. That is the way to avoid unnec-
essary radiation and to reduce costs of treatment 
16. The
clinical images of both patients clearly indicated perforation
and radiography just confirmed it. In spite of the fact that we
did esophagogram in all of the patients immediately after the
dilatation, the mentioned experience suggests radiography
only in case of doubt in perforation.
The majority of authors come to a conclusion that
achalasia equally affects both sexes which was confirmed by
our study, so that the ratio males to females is 1.2 : 1. There
are, however, opposite data, thus some authors claim that
achalasia is two times as present in males than in females,
while the others claim quite the opposite 
42.
Balloon dilatation efficacy measured by the symptome
score regarding sex had no statistical significance in our
study which is in accordance with data presented by other
authors
 5, 38, 45–50.
According to our study, the disease is most frequent in
the third decade of life, although in females it prevails at 40
to 50 years of age. The average age of our patients was 43
that also corresponds with data from the literature, while Ko-
dakia and Wong 
16 state 52, and Mikaeli et al. 
49 35.5 years.
There is no significant difference in efficacy of dilatation re-
garding age. However, dilatation results are worse in patients
under 40 with the significance of p < 0.05. There is no a gen-
erally accepted attitude, however, the majority of authors re-
port worse results in younger patients 
1, 38.
Ever since introducing dilatation into the treatment of
achalasia, numerous authors had tried to define risk factors
that could anticipate the outcome of dilatation and in so do-
ing sellect the patients that would have good response and
the others treat surgically.
It is reported most frequently that there is no correlation
of the duration of symptoms with good response 
20. In our
study we did not find a significant correlation of the duration
of symptoms before dilatation with the efficacy of dilatation.
The majority of authors confirmed no correlation of
body weight reduction with the efficacy of dilatation, which
is also confirmed in our study 
5, 51, 52 . In our study, there were
patients with a significant body weight loss and excellent re-
sults, as well as a low body weight loss and bad results.
Higher loss in body weight within a short time period sug-
gests the need to exclude malignacy and perform additional
diagnostics not standard for achalasia diagnostics (computed
tomography, echo endosonography). These procedures could
predict cancer due to perineural myenteric esophageal plexus
infiltration by pancreatic and suprarenalis cancers 
38.
Vantreppen and Hellemans 
5 were the first to point out
that monitoring of body weight rise could estimate dilatation
efficacy 
5. Body weight loss together with dysphagia is the
major symptom of achalasia, thus it seems logical that
monitoring of body weight rise could suggest dilatation out-
come. In our series, 92% of the patients had body weight loss
prior to dilatation, while 80% of the patient had body weight
loss after dilatation. Body weight rise directly correlates with
dilatation efficacy. So, by monitoring body weight, both
physicians and patients could estimate dilatation efficacy in a
simple, objective, measurable an acceptable way.
There is a controversy of predicting dilatation outcome
on the basis of esophageal lumen width. Ponce et al. 
50 re-
ports such correlation having a high significance, while other
authors conclude that there is no significant correlation of
esophageal lumen width prior to dilatation with dilatation ef-
ficacy 
9, 20, 41. In our study there was no significant correlation
of esophageal lumen width prior to dilatation which is logi-
cally to expect since dilatation is paliative and irreversible.
There is no predictive model which could be used for
identification of patients who might have bad dilatation re-
sults and refer them to surgical treatment. The majority of
authors conclude that worse results could be expected in pa-
tients younger than 20 years, esophageal width less than 3
cm, esophageal basal pressure higher than 15 mmHg, and
DES pressure higher than 30 mmHg 
9, 20, 50, 53.
Some authors state that esophageal scintigraphy could
not replace manometry of the esophagus in the diagnostics of
motor skill disorder due to high number of false positive
findings 
53–55. Our study confirmed that scintigraphy of the
esophagus can most objecively estimate dilatation effect in
esophageal achalasia.
How many dilatations should be performed to be able to
definitively estimate the treatment of achalasia by dilatation?
If dilatation is unsuccessful, Vantrepen and Hellemans 
5 con-
sider that dilatation efficacy significantly rises by favorable
dilatations, and recommend maximally four repeated dilata-
tions. Richter 
23 and the American Association of Gastroin-
testinal Endoscopy recommend two dilatations, and than re-
fer a patient to surgery if dilatation was not efficient. Koda-
kia and Wong 
16 state that increasing the number of dilata-
tions does not significantly increase dilatation efficacy. Lake
and Wong 
42 come to a conclusion that dilatation efficacy
rises up to two reinterventions, and that higher number of
dilatations is not justified also due to treatment costs. Our
study confirmed that dilatation efficacy rises with one or two
redilatations. We did not have patients with more than three
dilatations. In about two thirds of the patients excellent re-
sults were obtained after first dilatation, while after repeated
dilatations the results were excellent or good in 89% of the
patients. In other words, if repeated dilatations were not per-
formed, the 12 more patients would have been operated on.
Perforation is the major complication of dilatation in
achalasia affecting 2% to 6% of dilated patients. There were
two perforations in our study, both in males, of which one oc-
cured in first and one in repeated dilatation. They were lacal-
ized above DES to the left in the form of longitudinal rupture
of 2–3 cm. Borotto et al. 
40 analysed eight perforations con-Volumen 70, Broj 10 VOJNOSANITETSKI PREGLED Strana 921
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cluding that they are more frequent in patients with less body
weight loss and high amplitude of esophageal contraction.
Other authors conclude that there are no clearly defined risk
factors for perforation, making it impossible to identify pa-
tients with a high risk of perforation 
1, 5, 40, 44. Contrary to the
fact that the literature tells that the majority of perforations are
treated conservatively, both of our patients were operated on.
The application of botulinum toxin remains as alterna-
tive for patients with risky operation or dilatation or in those
patients who do not accept dilatation for any reason 
56–65.
The most recent studies suggest that laparoscopy has
good results and that its application increases leaving con-
ventional surgery as alternative 
66–68.
Peroral endoscopic myotomy (PEM) was developed by
Inoue et al. 
68 to ensure less invasive approach to achalasia
treatment.
Conclusion
The use of modified balloon dilatation in achalasia
treatment resulted in excellent and good results in 88% of the
patients. The patients above 40 years as compared to younger
ones showed better clinical response. Perforation was re-
corded in 3.67% of the patients without lethal outcome. A
modified dilatation technique is efficious and safe method in
the initial achalasia treatment.
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